Dr. Zaki Fadlullah Wilmot

Assistant Professor (Research Track) | Oncological Sciences | University of Utah

About Me

Welcome to my research webpage! I am an Assistant Professor (Research Track) at the University of Utah, specializing in bioinformatics and computational oncology. My research bridges computational approaches with translational oncology, contributing to clinically meaningful discoveries.

I received my Ph.D. in Medicine (Computational Biology focused) from the University of Manchester in 2022, and my BSc (First Class) in Biomedical Science from the University of Queensland in 2011.

My current research interests include:

  • Pan-cancer scRNA-seq analysis for drug discovery
  • Immune-related adverse events and immunotherapy efficacy
  • Plasma cfDNA genomics for prostate cancer prognosis
  • Clinical trial data mining and pattern recognition

Research Projects

Pan-Cancer scRNA-seq Drug Discovery

Focus: Immunotherapy toxicity and efficacy

Analyzing pan-cancer single-cell RNA sequencing data to discover targetable drug candidates that mitigate immune-related adverse events while preserving immunotherapy efficacy. This work aims to improve patient outcomes by reducing toxicity without compromising treatment effectiveness.

Prostate Cancer Genomics

Focus: Plasma cfDNA and clinical outcomes

Utilizing plasma cell-free DNA whole genome sequencing to develop and implement multi-gene risk score algorithms for predicting clinical outcomes in prostate cancer patients. This research contributes to personalized medicine approaches in oncology.

Clinical Trial Data Mining

Focus: Immunotherapy toxicity patterns

Analysis of over 400,000 clinical trials to identify patterns of immunotherapy toxicity. This large-scale data analysis helps understand adverse event profiles and improve patient safety in cancer treatment.

Selected Publications

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Williamson, J., Fadlullah, M.Z.H., Kovacsovics-Bankowski, M., et al.
Current Oncology, 32(3), (2025)

Investigation of high-dose ipilimumab combination therapy effectiveness in advanced melanoma patients who progressed on standard treatments.

Multi-gene risk-score for prediction of clinical outcomes in treatment-naïve metastatic castrate resistant prostate cancer
Fadlullah, M.Z.H., Nix, D., Herberts, C., et al.
JNCI Cancer Spectrum, (2025)

Development of a multi-gene risk scoring algorithm using plasma cfDNA whole genome sequencing for predicting clinical outcomes in prostate cancer.

Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials
Fadlullah, M.Z.H., Lin, C.N., Coleman, S., et al.
The Oncologist, (2024)

Comprehensive analysis of over 400,000 clinical trials to identify patterns and predictors of immunotherapy-related adverse events.

For a complete list of 35+ publications, see my Google Scholar profile.

Curriculum Vitae

You can download my complete CV here: CV PDF

Education

Professional Experience

Awards & Honors

Contact Information

Email: zaki.wilmot@hci.utah.edu
Office: Huntsman Cancer Institute
Institution: University of Utah
Location: Utah, United States

Find me online

ORCID | Google Scholar | LinkedIn